The recent report by Denton et al.  adds to previous well-designed negative placebo-controlled clinical trials of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). The primary endpoint was the weekly average number of RP attacks, with secondary endpoints including daily RP attack duration and RP severity (the single-item Raynaud's Condition Score [RCS]), that together comprise the RCS diary. The accompanying editorial, provides insightful suppositions of factors contributing to the disappointing performance of the RCS diary in clinical trials .
|Number of pages||2|
|Journal||Arthritis & Rheumatology|
|Early online date||7 Mar 2018|
|Publication status||Published - 1 Jun 2018|
ASJC Scopus subject areas
- Immunology and Allergy